deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05054257

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (UHKT-CAR19-01)

Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.

Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic

Conditions Non-Hodgkin's Lymphoma Refractory Non-Hodgkin's Lymphoma, Relapsed Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions Autologous CAR19 T lymphocytes
Updated 7 times since 2021 Last updated: Jan 3, 2025 Started: Jun 2, 2021 Primary completion: Jun 1, 2025 Completion: Dec 12, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Non-Hodgkin's Lymphoma Refractory and Non-Hodgkin's Lymphoma, Relapsed, this trial is actively recruiting participants. The trial is conducted by Institute of Hematology and Blood Transfusion, Czech Republic and has accumulated 7 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshotRecruiting~Sep 2022 – ~Feb 2024 · 17 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotRecruiting~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshotRecruiting~Feb 2025 – present · 17 months · monthly snapshotRecruiting

Change History

7 versions recorded

  1. Feb 2025 — Present [monthly]

    Recruiting PHASE1

  2. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 2 earlier versions

  1. Sep 2022 — Feb 2024 [monthly]

    Recruiting PHASE1

  2. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institute of Hematology and Blood Transfusion, Czech Republic
Data source: Institute of Hematology and Blood Transfusion, Czech Republic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations